I am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Justice Brett Kavanaugh Is Not An ‘Honest Person’ And ‘Must Know’ He Assaulted Christine Blasey Ford, She Reportedly Says In MemoirThe stellar success of blockbuster drugs like Ozempic, Wegovy, Mounjaro and Zepbound has companies eager to break into the lucrative weight loss drug market — here are the hopeful rivals preparing to challenge Eli Lilly and Novo Nordisk for dominance in the obesity drug gold rush.
There is no guarantee promising results on efficacy, safety and tolerability from earlier trials will be replicated in larger late-stage trials. Even companies with candidates already in the later stages of testing are still going to require several years to gather and process the data and, should things pan out, time to work with regulators to secure approval.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
More teens are using weight loss drugs like Wegovy and OzempicMarina Kopf is an associate producer with the NBC News Health and Medical Unit.
Read more »
Wegovy, Ozempic Use Could Complicate Your SurgeryWeight-loss drugs like Wegovy and Ozempic can increase a person’s risk of throwing up during surgery while under anesthesia, a new study reports.
Read more »
FDA approves Wegovy to reduce heart attack and stroke riskBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early TrialI am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Read more »
FDA approves Wegovy for cardiovascular diseaseThe FDA on Friday approved Wegovy to lower the risk of cardiovascular death for people who are obese or overweight, a first of its kind classification.
Read more »
FDA approves Wegovy for lowering heart attack and stroke risk in overweight patientsThe popular weight-loss drug can now be used to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or who have obesity, the FDA said.
Read more »